Cell remedy developer Arcellx claims its lead program may very well be a safer different to at the moment out there CAR T therapies for a number of myeloma, noting that beforehand reported preliminary information present no worrisome neurological problems. Extra detailed information offered on the American Society of Hematology's annual assembly builds on the security profile of Gilead Sciences' […]
